oral zidovudine
Recently Published Documents


TOTAL DOCUMENTS

18
(FIVE YEARS 0)

H-INDEX

11
(FIVE YEARS 0)

2013 ◽  
Vol 13 (1) ◽  
Author(s):  
Jennifer Neubert ◽  
Maren Pfeffer ◽  
Arndt Borkhardt ◽  
Tim Niehues ◽  
Ortwin Adams ◽  
...  
Keyword(s):  

HIV Medicine ◽  
2007 ◽  
Vol 8 (7) ◽  
pp. 451-456 ◽  
Author(s):  
M Mirochnick ◽  
JH Rodman ◽  
BL Robbins ◽  
A Fridland ◽  
J Gandía ◽  
...  

AIDS ◽  
2000 ◽  
Vol 14 (5) ◽  
pp. 509-516 ◽  
Author(s):  
Chaiporn Bhadrakom ◽  
R. J. Simonds ◽  
Joanne V. Mei ◽  
Suvanna Asavapiriyanont ◽  
Varaporn Sangtaweesin ◽  
...  

1999 ◽  
Vol 43 (12) ◽  
pp. 3046-3046
Author(s):  
Diana P. Callender ◽  
Nalina Jayaprakash ◽  
Aaron Bell ◽  
Vidmantas Petraitis ◽  
Ruta PetraItiene ◽  
...  
Keyword(s):  

The Lancet ◽  
1999 ◽  
Vol 354 (9195) ◽  
pp. 2050-2051 ◽  
Author(s):  
F Dabis ◽  
L Dequae-Merchadou ◽  
V Leroy ◽  
L Mandelbrot ◽  
C Welffens-Ekra

1999 ◽  
Vol 43 (4) ◽  
pp. 972-974 ◽  
Author(s):  
Diana P. Callender ◽  
Nalini Jayaprakash ◽  
Aaron Bell ◽  
Vidmantas Petraitis ◽  
Ruta Petratienes ◽  
...  

ABSTRACT The pharmacokinetic profile of oral zidovudine entrapped in a 50:50 polyactide-coglycolide matrix (nanospheres) was compared to those of standard oral and parenteral zidovudine formulations in rabbits. The bioavailability of zidovudine nanospheres at 50 mg/kg of body weight was 76%, and this dose achieved prolonged exposure to zidovudine compared to standard formulations without an increase in the drug’s peak concentration.


The Lancet ◽  
1999 ◽  
Vol 353 (9155) ◽  
pp. 781-785 ◽  
Author(s):  
Stefan Z Wiktor ◽  
Ehounou Ekpini ◽  
John M Karon ◽  
John Nkengasong ◽  
Chantal Maurice ◽  
...  

AIDS ◽  
1994 ◽  
Vol 8 (5) ◽  
pp. 635-640 ◽  
Author(s):  
Molly Nozyce ◽  
Mara Hoberman ◽  
Stephen Arpadi ◽  
Andrew Wiznia ◽  
Genevieve Lambert ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document